C4 Therapeutics, Inc.
General ticker "CCCC" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $178.0M (TTM average)
C4 Therapeutics, Inc. follows the US Stock Market performance with the rate: 26.8%.
Estimated limits based on current volatility of 4.7%: low 2.50$, high 2.75$
Factors to consider:
- Total employees count: 110 (-24.1%) as of 2024
- Top business risk factors: Profitability and sustainability, Operational and conduct risks, Labor/talent shortage/retention, Litigation risks, Economic downturns and volatility
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [2.22$, 5.76$]
- 2025-12-31 to 2026-12-31 estimated range: [1.80$, 4.74$]
Financial Metrics affecting the CCCC estimates:
- Positive: with PPE of -2.5 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -24.56 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Net income
- Positive: 41.86 < Shareholder equity ratio, % of 61.78 <= 63.39
Short-term CCCC quotes
Long-term CCCC plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $31.10MM | $20.76MM | $35.58MM |
| Operating Expenses | $160.63MM | $159.79MM | $155.20MM |
| Operating Income | $-129.53MM | $-139.03MM | $-119.61MM |
| Non-Operating Income | $1.36MM | $7.82MM | $14.43MM |
| Interest Expense | $2.22MM | $1.37MM | $0.00MM |
| R&D Expense | $117.84MM | $117.71MM | $110.64MM |
| Income(Loss) | $-128.18MM | $-131.21MM | $-105.19MM |
| Taxes | $0.00MM | $1.28MM | $0.13MM |
| Profit(Loss)* | $-128.18MM | $-132.49MM | $-105.32MM |
| Stockholders Equity | $289.23MM | $246.11MM | $215.99MM |
| Inventory | $60.96MM | $0.00MM | $0.00MM |
| Assets | $430.84MM | $376.45MM | $349.60MM |
| Operating Cash Flow | $-105.94MM | $-106.84MM | $-65.16MM |
| Capital expenditure | $5.50MM | $1.71MM | $0.18MM |
| Investing Cash Flow | $58.42MM | $158.35MM | $-51.27MM |
| Financing Cash Flow | $1.15MM | $45.49MM | $45.34MM |
| Earnings Per Share** | $-2.62 | $-2.67 | $-1.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.